Abstract

CONVALESCENT PLASMA THERAPY TREATMENT IN COVID 19 SITUATIONS FOR MODERATE ASWELL CRITICAL PATIENTS

Ramiz Abdulgani Shaikh* and Somesh Prabhakar Purankar

ABSTRACT

COVID 19 mainly consists of SARS COVID 19 genes. The recovered plasma obtained from the COVID 19 donor is obtained. It contains IgG and IgM anti-SCAR COVI-19 which attack the ACE2 receptor and avoid proteolysis and genomic replication. Plasma transfusion carriers a number of risk i.e TRALI, TACO, allergic reaction and pathogen related reaction. The people with ARDS not responsive to the drug treatment are treated with (CPT). The patients with ARDS usually have no response to the drug and liable to organ failure. The treatment shows better response if treated in moderate stage of COVID 19. Importance: convalescent plasma therapy is major therapeutic option for COVID 19 patients with severe cases. As of now there is no the therapeutic treatment for SARS-CO-VI-2. It is better to use CPT with other Supportive medicaments and instruments. We have carried out various searches in clinicaltrials.gov and pubmed and various other portals and studied various clinical trials for convalescent plasma transfusions. The following article gives the sight of same.

Keywords: MERS, COVID19, Intravenous immunoglobulin’s, ACE-2, CPT, ADRS, Neutralizing antibodies, Prophylaxis, etc.